A Radomized Clinical Trial on the Clinical Efficacy and Toxicities of Single-agent Paclitaxel Liposome versus Paclitaxel Liposome plus Oxaliplatin as First-line Chemotherapy for Advanced Non-small Cell Lung Cancer in Elderly Patients
Background and objective The third generation single-agent drug has been recommended as a first-line chemotherapy for elderly patients with advanced non-small cell lung cancer (NSCLC). The aim of the current radomized trial is to compare the clinical efficacy and toxicities of single-agent paclitaxe...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2012-02-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2012.02.04 |
id |
doaj-bfb9478c25494b3eb9f2c6b0e61f637c |
---|---|
record_format |
Article |
spelling |
doaj-bfb9478c25494b3eb9f2c6b0e61f637c2020-11-25T00:40:06ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872012-02-01152848910.3779/j.issn.1009-3419.2012.02.04A Radomized Clinical Trial on the Clinical Efficacy and Toxicities of Single-agent Paclitaxel Liposome versus Paclitaxel Liposome plus Oxaliplatin as First-line
Chemotherapy for Advanced Non-small Cell Lung Cancer in Elderly PatientsXiaomei ZENGZhixi LIMei HOUBackground and objective The third generation single-agent drug has been recommended as a first-line chemotherapy for elderly patients with advanced non-small cell lung cancer (NSCLC). The aim of the current radomized trial is to compare the clinical efficacy and toxicities of single-agent paclitaxel liposome versus paclitaxel liposome plus oxaliplatin as a first-line chemotherapy for elderly patients. Methods Sixty-nine advanced NSCLC patients from July 2008 to August 2010, confirmed with pathology or cytology and had never received treatment, were randomly divided into two groups. The first group was given 135 mg/m2 of single-agent paclitaxel liposome on day 1 of each cycle. The second group was given 135 mg/m2 paclitaxel liposome plus 125 mg/m2 oxaliplatin on day 1 of each cycle. One cycle is composed of 21 days. Efficacy and toxicities could be evaluated after two or more cycles. Results No statistical differences were observed between the two groups in terms of efficacy (22.9% vs 35.3%, P=0.297), disease control rate (60.0% vs 70.6%, P=0.450), and 1-year survival rate (28.6% vs 41.2%, P=0.724). However, the group treated with paclitaxel liposome plus oxaliplatin had longer progression free survival (PFS) (5.0 months vs 3.5 months, P=0.024). In addition, the toxicities that occurred in the two groups were similar including leukocytopenia (P=0.808), thrombocytopenia (P>0.999), anemia (P=0.477), and nausea/vomiting (P=0.777). The number of neurotoxicity that occurred in the two groups were 33 and 3 (97.1% vs 8.6%, P<0.001), respectively. However, all were grade I-II. Conclusion The clinical efficacy of paclitaxel liposome plus oxaliplatin as a first-line chemotherapy for elderly patients with advanced NSCLC is more better than that of the single-agent paclitaxel liposome. It prolongs PFS and is safe for clinical use.http://dx.doi.org/10.3779/j.issn.1009-3419.2012.02.04Paclitaxel liposomeOxaliplatinLung neoplasmsAged |
collection |
DOAJ |
language |
zho |
format |
Article |
sources |
DOAJ |
author |
Xiaomei ZENG Zhixi LI Mei HOU |
spellingShingle |
Xiaomei ZENG Zhixi LI Mei HOU A Radomized Clinical Trial on the Clinical Efficacy and Toxicities of Single-agent Paclitaxel Liposome versus Paclitaxel Liposome plus Oxaliplatin as First-line Chemotherapy for Advanced Non-small Cell Lung Cancer in Elderly Patients Chinese Journal of Lung Cancer Paclitaxel liposome Oxaliplatin Lung neoplasms Aged |
author_facet |
Xiaomei ZENG Zhixi LI Mei HOU |
author_sort |
Xiaomei ZENG |
title |
A Radomized Clinical Trial on the Clinical Efficacy and Toxicities of Single-agent Paclitaxel Liposome versus Paclitaxel Liposome plus Oxaliplatin as First-line
Chemotherapy for Advanced Non-small Cell Lung Cancer in Elderly Patients |
title_short |
A Radomized Clinical Trial on the Clinical Efficacy and Toxicities of Single-agent Paclitaxel Liposome versus Paclitaxel Liposome plus Oxaliplatin as First-line
Chemotherapy for Advanced Non-small Cell Lung Cancer in Elderly Patients |
title_full |
A Radomized Clinical Trial on the Clinical Efficacy and Toxicities of Single-agent Paclitaxel Liposome versus Paclitaxel Liposome plus Oxaliplatin as First-line
Chemotherapy for Advanced Non-small Cell Lung Cancer in Elderly Patients |
title_fullStr |
A Radomized Clinical Trial on the Clinical Efficacy and Toxicities of Single-agent Paclitaxel Liposome versus Paclitaxel Liposome plus Oxaliplatin as First-line
Chemotherapy for Advanced Non-small Cell Lung Cancer in Elderly Patients |
title_full_unstemmed |
A Radomized Clinical Trial on the Clinical Efficacy and Toxicities of Single-agent Paclitaxel Liposome versus Paclitaxel Liposome plus Oxaliplatin as First-line
Chemotherapy for Advanced Non-small Cell Lung Cancer in Elderly Patients |
title_sort |
radomized clinical trial on the clinical efficacy and toxicities of single-agent paclitaxel liposome versus paclitaxel liposome plus oxaliplatin as first-line
chemotherapy for advanced non-small cell lung cancer in elderly patients |
publisher |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
series |
Chinese Journal of Lung Cancer |
issn |
1009-3419 1999-6187 |
publishDate |
2012-02-01 |
description |
Background and objective The third generation single-agent drug has been recommended as a first-line chemotherapy for elderly patients with advanced non-small cell lung cancer (NSCLC). The aim of the current radomized trial is to compare the clinical efficacy and toxicities of single-agent paclitaxel liposome versus paclitaxel liposome plus oxaliplatin as a first-line chemotherapy for elderly patients. Methods Sixty-nine advanced NSCLC patients from July 2008 to August 2010, confirmed with pathology or cytology and had never received treatment, were randomly divided into two groups. The first group was given 135 mg/m2 of single-agent paclitaxel liposome on day 1 of each cycle. The second group was given 135 mg/m2 paclitaxel liposome plus 125 mg/m2 oxaliplatin on day 1 of each cycle. One cycle is composed of 21 days. Efficacy and toxicities could be evaluated after two or more cycles. Results No statistical differences were observed between the two groups in terms of efficacy (22.9% vs 35.3%, P=0.297), disease control rate (60.0% vs 70.6%, P=0.450), and 1-year survival rate (28.6% vs 41.2%, P=0.724). However, the group treated with paclitaxel liposome plus oxaliplatin had longer progression free survival (PFS) (5.0 months vs 3.5 months, P=0.024). In addition, the toxicities that occurred in the two groups were similar including leukocytopenia (P=0.808), thrombocytopenia (P>0.999), anemia (P=0.477), and nausea/vomiting (P=0.777). The number of neurotoxicity that occurred in the two groups were 33 and 3 (97.1% vs 8.6%, P<0.001), respectively. However, all were grade I-II. Conclusion The clinical efficacy of paclitaxel liposome plus oxaliplatin as a first-line chemotherapy for elderly patients with advanced NSCLC is more better than that of the single-agent paclitaxel liposome. It prolongs PFS and is safe for clinical use. |
topic |
Paclitaxel liposome Oxaliplatin Lung neoplasms Aged |
url |
http://dx.doi.org/10.3779/j.issn.1009-3419.2012.02.04 |
work_keys_str_mv |
AT xiaomeizeng aradomizedclinicaltrialontheclinicalefficacyandtoxicitiesofsingleagentpaclitaxelliposomeversuspaclitaxelliposomeplusoxaliplatinasfirstlinechemotherapyforadvancednonsmallcelllungcancerinelderlypatients AT zhixili aradomizedclinicaltrialontheclinicalefficacyandtoxicitiesofsingleagentpaclitaxelliposomeversuspaclitaxelliposomeplusoxaliplatinasfirstlinechemotherapyforadvancednonsmallcelllungcancerinelderlypatients AT meihou aradomizedclinicaltrialontheclinicalefficacyandtoxicitiesofsingleagentpaclitaxelliposomeversuspaclitaxelliposomeplusoxaliplatinasfirstlinechemotherapyforadvancednonsmallcelllungcancerinelderlypatients AT xiaomeizeng radomizedclinicaltrialontheclinicalefficacyandtoxicitiesofsingleagentpaclitaxelliposomeversuspaclitaxelliposomeplusoxaliplatinasfirstlinechemotherapyforadvancednonsmallcelllungcancerinelderlypatients AT zhixili radomizedclinicaltrialontheclinicalefficacyandtoxicitiesofsingleagentpaclitaxelliposomeversuspaclitaxelliposomeplusoxaliplatinasfirstlinechemotherapyforadvancednonsmallcelllungcancerinelderlypatients AT meihou radomizedclinicaltrialontheclinicalefficacyandtoxicitiesofsingleagentpaclitaxelliposomeversuspaclitaxelliposomeplusoxaliplatinasfirstlinechemotherapyforadvancednonsmallcelllungcancerinelderlypatients |
_version_ |
1725291378668208128 |